An early Alzheimer's treatment that removes amyloid plaques from the brain many years before symptoms arise may help delay ...

Amyloidosis is the basis of several serious diseases, such as Alzheimer disease and Parkinson disease. This process involves the formation of amyloid fibrils, crystal-like collections of misfolded ...

Splash Clinical and C2N Diagnostics have collaborated to enhance the recruitment process for clinical trials of Alzheimer's ...

Eli Lilly (LLY) stock in focus as an expert panel of the EU drug regulator declines to endorse its Alzheimer's drug Kisunla.

Research shows experimental anti-amyloid drug reduced cognitive symptom risk by 50% in people with rare genetic mutations ...

A study published in Brain Communications revealed new insights into early detection of Alzheimer’s disease. Researchers have ...

Erwin Schrödinger, a theoretical physicist steeped in the philosophy of Schopenhauer and the Upanishads, delivered a series ...

The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...

The EU medicines regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's ability to slow cognitive ...

Washington University School of Medicine led a study evaluating long-term gantenerumab treatment in individuals with dominantly inherited Alzheimer's disease (DIAD). Gantenerumab was associated with ...

The European Medicines Agency has rejected Lilly’s Alzheimer’s drug Kisunla for a license, saying its benefits don’t outweigh ...